Annual Report 2025

CHAIRMAN’S STATEMENT 9 The United Laboratories International Holdings Limited Annual Report 2025 Enhancing Quality and Efficiency, and Achieving High-Quality Development In 2025, Artificial Intelligence (AI) technology achieved significant breakthroughs and widespread application globally, accelerating its transition from technological exploration to large-scale implementation. During the year, seven ministries, including the Ministry of Industry and Information Technology, jointly issued the “Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025- 2030)”, outlining a clear blueprint for the industry’s digital and intelligent transformation. With keen strategic insight, the Group is fully embracing the AI wave. We are actively advancing our AI strategic deployment, continuously promoting the deep integration of artificial intelligence with core business functions such as R&D, production, and management. We aim to improve quality and efficiency through AI technologies, injecting new momentum into high- quality development. In team building, we adhere to a people-oriented philosophy, continuously improving our institutional systems and optimising incentive mechanisms. We are dedicated to building a talent team that is friendly, responsible, diligent, efficient, and possesses an international perspective and capabilities. During the Year, the United Laboratories Craftsman Training School was successfully launched, which will continuously supply professionally skilled talent for regional industrial upgrading. During the Year, the Group steadily advanced capacity upgrades, with several key construction projects successfully coming to fruition. Relying on our comprehensive industrial chain advantages, we con t i nuous l y enhance t he Gr oup ’s ove r a l l competitiveness, comprehensively empowering its high-quality development. Environmental, Social and Governance Upholding the corporate mission of “Making Life More Valuable”, the Group integrates the concept of sustainable development into its business operations and decision-making. We actively fulfill our social responsibilities by continuously investing in various fields such as education, disaster relief, and community care to contribute to the society. Simultaneously, we respond wholeheartedly to the national policy of green and sustainable development, promoting industrial upgrading and facilitating the green and low-carbon transformation of enterprises. Facing the profound impacts of global climate change, we proactively incorporate climate risk response and opportunity identification into our strategic vision. We actively identify climate-related risks and opportunities within our production operations and value chain, promote energy conservation, emission reduction, and energy structure optimisation, explore application scenarios for low-carbon technologies in the pharmaceutical sector, and seek breakthroughs in green manufacturing and the recycling economy. We are committed to transforming climate challenges into new drivers for innovative development. Outlook The Central Economic Work Conference in 2025 clearly positioned biomedicine as an “emerging pillar industry”, sending a clear policy signal to “promote the high- quality development of innovative drugs”. Currently, with clinical value at its core, the industry is building a new pattern for high-quality development characterised by “source innovation, intelligent manufacturing, and global presence”, laying a solid foundation for entering the 15th Five-Year Plan period.